RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC

(MedPage Today) -- MADRID -- First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news